Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The detection and quantification of hepatitis B virus (HBV) DNA plays an important role in diagnosing and monitoring HBV infection as well as in assessing the therapeutic response. We compared the analytical performance of a random access, fully automated HBV assay—DxN VERIS Molecular Diagnostics System (Beckman Coulter, Brea, CA, USA)—with that of Abbott RealTime HBV assay (Abbott Laboratories, Des Plaines, IL, USA). The between-day precision of the VERIS assay ranged from 0.92% (mean 4.68 log IU/mL) to 4.15% (mean 2.09 log IU/mL) for pooled sera from HBV patients. HBV DNA levels measured by the VERIS HBV assay correlated with the calculated HBV DNA levels (r2=0.9994; P<0.0001). The lower limit of quantification was estimated as 8.76 IU/mL (Probit analysis, 95% confidence interval: 7.32–12.00 IU/mL). Passing-Bablok regression analysis showed good concordance between the VERIS and RealTime assays for 187 chronic HBV samples (y=-0.2397+0.9712x; r=0.981), as well as for 20 drug-resistant HBV genotype C positive samples (y=-0.5415+0.9954x; r=0.961). The VERIS assay demonstrated performance similar to the RealTime assay and is suitable for high-throughput HBV DNA monitoring in large hospital laboratories.
Abstract
The detection and quantification of hepatitis B virus (HBV) DNA plays an important role in diagnosing and monitoring HBV infection as well as in assessing the therapeutic response. We compared the analytical performance of a random access, fully automated HBV assay—DxN VERIS Molecular Diagnostics System (Beckman Coulter, Brea, CA, USA)—with that of Abbott RealTime HBV assay (Abbott Laboratories, Des Plaines, IL, USA). The between-day precision of the VERIS assay ranged from 0.92% (mean 4.68 log IU/mL) to 4.15% (mean 2.09 log IU/mL) for pooled sera from HBV patients. HBV DNA levels measured by the VERIS HBV assay correlated with the calculated HBV DNA levels (r2=0.9994; P<0.0001). The lower limit of quantification was estimated as 8.76 IU/mL (Probit analysis, 95% confidence interval: 7.32–12.00 IU/mL). Passing-Bablok regression analysis showed good concordance between the VERIS and RealTime assays for 187 chronic HBV samples (y=-0.2397+0.9712x; r=0.981), as well as for 20 drug-resistant HBV genotype C positive samples (y=-0.5415+0.9954x; r=0.961). The VERIS assay demonstrated performance similar to the RealTime assay and is suitable for high-throughput HBV DNA monitoring in large hospital laboratories.
참고문헌 (16)
- Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
- Zhang Q, "Incidence of natural resistance mutations in naïve chronic hepatitis B patients : a systematic review and meta-analysis", J Gastroenterol Hepatol, 30, pp.252~261 (2015)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- 한미순, "Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep", COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients, 2017, pp.37(3), 248~253[DOI]
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Pawlotsky JM, "Virologic monitoring of hepatitis B virus therapy in clinical trials and practice : recommendations for a standardized approach", Gastroenterology, 134, pp.405~415 (2008)
- Chevaliez S, "Performance of version 2.0 of the Cobas AmpliPrep", Cobas TaqMan Real-time PCR assay for hepatitis B virus DNA quantification, 2010, pp.48, 3641~3647
- Chevaliez S, "New virologic tools for management of chronic hepatitis B and C", Gastroenterology, 142, pp.1303~1313 (2012)[DOI]
- Yeh ML, "Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep", Cobas TaqMan HBV assay for HBV DNA detection and quantification, 2014, pp.60, 206~214
- Fourati S, "Evaluation of a new random-access HBV DNA molecular assay : The VERIS HBV assay", J Clin Virol, 92, pp.69~74 (2017)
- Braun P, "A European multicentre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit", J Clin Virol, 95, pp.76~83 (2017)
- The Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
- 허희재, "Performance of the Real-Q EBV Quantification Kit for Epstein-Barr Virus DNA Quantification in Whole Blood", Annals of Laboratory Medicine, 37(2), pp.147~150 (2017), 대한진단검사의학회
- 김한아, "Automated Nucleic Acid Extraction Systems for Detecting Cytomegalovirus and Epstein-Barr Virus Using Real-Time PCR: A Comparison Study Between the QIAsymphony RGQ and QIAcube Systems", Annals of Laboratory Medicine, 37(2), pp.129~136 (2017), 대한진단검사의학회
- 박종은, "Performance Evaluation of the Real-Q Cytomegalovirus (CMV) Quantification Kit Using Two Real-Time PCR Systems for Quantifying CMV DNA in Whole Blood", Annals of Laboratory Medicine, 36(6), pp.603~606 (2016), 대한진단검사의학회
- 조지현, "B형간염바이러스 유전자형의 국내 분포에 대한 연구", Clinical and Molecular Hepatology, 15(2), pp.140~147 (2009), 대한간학회